Results 181 to 190 of about 1,892,074 (261)

Ultrasound‐Recharged Sub‐Nanometer Palladium Catalysts for on‐Demand and Self‐Terminating Bioorthogonal Prodrug Activation in Cancer Therapy

Advanced Science, EarlyView.
Safe and precise bioorthogonal therapy of tumors was achieved by an ultrasound‐responsive heterostructured nanoreactor with on‐demand catalytic activity. Under piezoelectric catalysis, the system undergoes reversible Pd2+/Pd0 redox cycling, concurrently enabling spatiotemporally controlled prodrug activation and self‐terminating catalytic dose ...
Daqing Xia, Lei Liu, Shuang Jin, Guangxu Fang, Chang Yu, Yunyun Wu, Lunli Xiang, Hongrui Zhu, Zhenqiang Wang, Jixi Zhang   +9 more
wiley   +1 more source

Harnessing Large‐Scale Multi‐Omics Data for Risk Prediction and Deep Phenotyping of Valvular Heart Diseases in the General Population

Advanced Science, EarlyView.
Large‐scale UK Biobank analyses identify clinical and proteomic signatures for early prediction of valvular heart disease and its subtypes. Proteins add predictive value for VHD, AVS, and MVR, with outcome‐specific compact panels showing translational potential. Multi‐layer evidence highlights matrix remodeling, protease regulation, immune inflammation,
Zhihao Jiang, Yang Liu, Mingyu Song, Ning Chen, Canqing Yu, Jun Lv, Eric Yuk Fai Wan, Lu Qi, Liming Li, Dianjianyi Sun, Bang Zheng   +10 more
wiley   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

Advanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo, Hansen Lin, Haoqian Feng, Lei Tan, Xi Liu, Yong Huang, Junjie Cen, Jiajie Chen, Xinwei Zhou, Mingjie Lin, Wuyuan Liao, Zheyu Ai, Minyu Chen, Yinghan Wang, Wei Chen, Junhang Luo, Yanping Liang   +16 more
wiley   +1 more source

NIR‐II Light‐Triggered Electron Flow Initiates Cuproptosis‐Centered Thermoelectric‐Immunotherapy for Breast Cancer

Advanced Science, EarlyView.
A NIR‐II light‐activatable thermoelectric nanoreactor converts surface‐bound Cu2+ into bioactive Cu+ via directed electron flow. This spatiotemporally controlled reduction triggers potent cuproptosis and immunogenic cell death, eradicating primary tumors and, together with aPD‐1 therapy, suppressing metastases while establishing durable immune memory ...
Boyu Yuan, Qin Fan, Shushu Chu, Shining Yang, Yuechao Yang, Chenxi Zhang, Jinqiao Zhang, Xinran Qu, Yiju Wei, Xin Wang, Ziliang Dong   +10 more
wiley   +1 more source

T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections.

Immunity, 2016
Daniel T. Utzschneider, M. Charmoy, Vijaykumar Chennupati, Laurène Pousse, D. Ferreira, Sandra P. Calderon-Copete, M. Danilo, Francesca Alfei, M. Hofmann, D. Wieland, S. Pradervand, R. Thimme, D. Zehn, W. Held   +13 more
semanticscholar   +1 more source

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

Advanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten, Karen Beets, Tessa Schalley, Janne Verreycken, Gayel Duran, Daphne Lintsen, Lisa Schuetz, Xue Zhong, Rinke Nieuwschepen, Melissa Schepers, Brecht Moonen, Jeroen Bogie, Jana Van Broeckhoven, Carlo Heirman, Jurgen Van den Heuvel, Bart Vanderborght, Ismael Varela, Roxanne Nouille, Lotte Jacobs, Jessica Filtjens, Sabah Kasmi, Elise Seynaeve, Veronica Mavrovouna, Jana De Vrieze, Michael A. Brehm, Sandra Maréchal, Sophie Janssens, Florence Lambolez, Niels Hellings, Stefaan De Koker, Bieke Broux   +30 more
wiley   +1 more source

Targeting p21‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Advanced Science, EarlyView.
Schematic illustration of a biomimetic SKEV@AAV platform targeting p21‐high senescent Kupffer cells (sKCs) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). p21‐high sKCs accumulate in the PVTT microenvironment and establish an immunosuppressive, SASP‐rich environment that facilitates tumor cell proliferation and immune evasion.
Na Ta, Shuyi Wang, Boyan Zhang, Ning Liu, Yingchen Han, Aoran Liu, Ying Xu, Tingsong Chen, Ye Zhang, Qiuhua Luo, Tao Han   +10 more
wiley   +1 more source

A Pancreatitis‐Inspired Trypsinogen Nanoplatform Reprograms Tumor‐Associated Macrophages via NF‐κB for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao, Yu He, Wenhao Li, Bo Gong, Han Lin, Jianlin Shi, Yuan Yong, Wencheng Wu   +7 more
wiley   +1 more source

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Immunity, 2002
Steffen Jung, D. Unutmaz, P. Wong, G. Sano, K. de los Santos, T. Sparwasser, Shengjia Wu, Srilatha Vuthoori, Kyung Ko, F. Zavala, E. Pamer, D. Littman, R. Lang   +12 more
semanticscholar   +1 more source

Penfluridol Triggers GSDME‐Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy

Advanced Science, EarlyView.
A high‐throughput screen of FDA‐approved antipsychotics identifies penfluridol as a potent pyroptosis inducer acting via direct TTI1 inhibition. This triggers TNFA‐NFKB signaling and caspase‐8/‐3‐dependent GSDME cleavage. The compound stimulates antitumor immunity alone and synergizes with anti‐PD‐1 therapy, while low TTI1 expression emerges as a ...
Linfeng Li, Daishi Li, Danyao Chen, Yating Dian, Lei Yao, Hui Su, Ziyu Guo, Deze Zhao, Zihua Wu, Furong Zeng, Chunfang Zhang, Guangtong Deng   +11 more
wiley   +1 more source